1. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61:3071–3076. PMID:
11306489.
2. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101:2377–2380. PMID:
12424198.

3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348:2609–2617. PMID:
12826635.

4. Huang N, Kawano MM, Harada H, et al. Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood. 1993; 82:3721–3729. PMID:
8260709.

5. Okado T, Hawley RG. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int J Cancer. 1995; 63:823–830. PMID:
8847141.
6. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993; 82:3712–3720. PMID:
8260708.

7. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996; 87:1104–1112. PMID:
8562936.

8. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93:1658–1667. PMID:
10029595.

9. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003; 22:2417–2421. PMID:
12717418.
10. Wang X, Li C, Ju S, Wang Y, Wang H, Zhong R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma. 2011; 52:1991–1998. PMID:
21718132.

11. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer. 2001; 91:1219–1230. PMID:
11283920.

12. Feng Y, Wen J, Mike P, et al. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells Dev. 2010; 19:1289–1296. PMID:
20121456.

13. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002; 99:4525–4530. PMID:
12036884.

14. Lazarini M, Traina F, Winnischofer SM, Costa FF, Queiroz ML, Saad ST. Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL-10 expression in the stromal layers. Leuk Res. 2011; 35:1102–1107. PMID:
21511336.

15. Wobus M, Benath G, Ferrer RA, et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol. 2012; 40:867–876. PMID:
22705469.

16. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006; 66:184–191. PMID:
16397231.

17. Maruyama D, Watanabe T, Heike Y, et al. Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. Int J Hematol. 2008; 88:396–402. PMID:
18989635.

18. Jo DY, Rafii S, Hamada T, Moore MA. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest. 2000; 105:101–111. PMID:
10619866.

19. Barbieri F, Bajetto A, Stumm R, et al. Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res. 2008; 14:5022–5032. PMID:
18698020.

20. Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010; 107:20009–20014. PMID:
21041659.
21. Lee HJ, Lee K, Lee DG, et al. Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor. Clin Cancer Res. 2012; 18:3270–3280. PMID:
22553346.

22. Kim SW, Hwang JH, Jin SA, et al. Role of pertussis toxin-sensitive G protein-coupled receptor signaling in the proliferation of bone marrow mesenchymal stem cells. Korean J Hematol. 2007; 42:24–32.

23. Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood. 2005; 105:3793–3801. PMID:
15677562.

24. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000; 106:1331–1339. PMID:
11104786.

25. Psenák O, Sefc L, Sýkora V, Chang KT, Necas E. Cytokine gene expression in regenerating haematopoietic tissues of mice after cyclophosphamide treatment. Acta Haematol. 2003; 109:68–75. PMID:
12624490.

26. Lerman OZ, Greives MR, Singh SP, et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction. Blood. 2010; 116:3669–3676. PMID:
20631377.

27. Kim SW, Kim HY, Lee HJ, Yun HJ, Kim S, Jo DY. Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells. Leuk Lymphoma. 2009; 50:1163–1173. PMID:
19391039.

28. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113:4341–4351. PMID:
19139079.
